S
Sepp Leodolter
Researcher at Medical University of Vienna
Publications - 148
Citations - 9372
Sepp Leodolter is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 44, co-authored 148 publications receiving 8982 citations. Previous affiliations of Sepp Leodolter include Martin Luther University of Halle-Wittenberg & University of Vienna.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
TL;DR: The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women in this randomized, placebo-controlled, doubleblind trial.
Journal ArticleDOI
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years
Darron R. Brown,Susanne K. Kjaer,Kristjan Sigurdsson,Ole-Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo L. Pérez,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven-Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,N. Munoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine Bryan,Lisa Lupinacci,Katherine E. D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr +35 more
TL;DR: These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and -18 and are needed to fully ascertain the population-based impact and public health significance of these findings.
Journal ArticleDOI
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura,Sepp Leodolter,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Laura A. Koutsky,Suzanne M. Garland,Diane M. Harper,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Ronald W. Jones,Janine T. Bryan,Frank J. Taddeo,Oliver M Bautista,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Jorma Paavonen +21 more
TL;DR: Prophylactic administration of quadrivalent HPV vaccine was effective in preventing high-grade vulval and vaginal lesions associated with HPV16 or HPV18 infection in women who were naive to these types before vaccination.
Journal ArticleDOI
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Muñoz,Susanne K. Kjaer,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Warner K. Huh,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Lisa Lupinacci,Katherine E.D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +39 more
TL;DR: High-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures and in the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.
Journal ArticleDOI
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
Joakim Dillner,Joakim Dillner,Susanne K. Kjaer,Cosette M. Wheeler,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,F. Xavier Bosch,Elmar A. Joura,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Roger Maansson,Shuang Lu,Scott Vuocolo,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +36 more
TL;DR: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types and a substantial reduction in the burden of these diseases through 42 months of follow-up.